Holen Sie sich die Stockscreener-App
27.55
2.27%
-0.64
Handel nachbörslich:
27.55
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$28.19
Offen:
$28.18
24-Stunden-Volumen:
1.50M
Relative Volume:
0.92
Marktkapitalisierung:
$4.66B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
22.22
EPS:
1.24
Netto-Cashflow:
$315.22M
1W Leistung:
-8.40%
1M Leistung:
-2.55%
6M Leistung:
+14.08%
1J Leistung:
+13.66%
1-Tages-Spanne:
$27.42
$28.47
1-Wochen-Bereich:
$27.42
$30.30
52-Wochen-Spanne:
$22.22
$32.88
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ALKS | 27.55 | 4.66B | 1.51B | 333.35M | 315.22M | 1.24 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Brokerages Set Alkermes plc (NASDAQ:ALKS) PT at $35.42 - MarketBeat
Alkermes (NASDAQ:ALKS) Price Target Raised to $40.00 at Mizuho - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Sold by Principal Financial Group Inc. - MarketBeat
Alkermes to Participate in Two Upcoming Investor Conferences - Lelezard
Alkermes (ALKS) to Present at Major Healthcare Conferences: Stifel and Jefferies London | ALKS Stock News - StockTitan
Trend Tracker for (ALKS) - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) Shares Purchased by Robeco Institutional Asset Management B.V. - MarketBeat
Van ECK Associates Corp Purchases 29,998 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Wellington Management Group LLP Adjusts Stake in Alkermes PLC - GuruFocus.com
Narcolepsy Insights from Alkermes Presented at Psych Congress and NEI Congress - Sleep Review
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences - PR Newswire
Alkermes EVP Craig Hopkinson sells $309,168 in stock - Investing.com
Alkermes EVP Craig Hopkinson sells $309,168 in stock By Investing.com - Investing.com Australia
Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com
Alkermes raised to buy by Stifel on increased confidence for ALKS2680 - MSN
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GuruFocus.com
Vanguard Group Inc's Recent Transaction in Alkermes PLC Shares - GuruFocus.com
Alkermes (NASDAQ:ALKS) Shares Gap UpHere's What Happened - MarketBeat
Alkermes raised to buy by Stifel on increased confidence for ALKS2680 (NASDAQ:ALKS) - Seeking Alpha
Alkermes PLC (ALKS) Shares Up 5.57% on Nov 5 - GuruFocus.com
Alkermes (NASDAQ:ALKS) Upgraded to Buy at Stifel Nicolaus - MarketBeat
A Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts - Benzinga
Stifel raises Alkermes target to $36, upgrades to buy By Investing.com - Investing.com Australia
Stifel raises Alkermes target to $36, upgrades to buy - Investing.com India
Alkermes plc (NASDAQ:ALKS) Holdings Decreased by DekaBank Deutsche Girozentrale - MarketBeat
(ALKS) Proactive Strategies - Stock Traders Daily
Short Interest in Alkermes plc (NASDAQ:ALKS) Drops By 7.9% - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Alkermes holds steady stock target with neutral rating amid royalty segment dip - Investing.com
Alkermes holds steady stock target with neutral rating amid royalty segment dip By Investing.com - Investing.com South Africa
Alkermes's SWOT analysis: innovative pipeline drives CNS stock's future - Investing.com
Alkermes Eyes Completion of Phase 2 Narcolepsy Studies in 2025 - Sleep Review
Goldman Sachs keeps Alkermes stock buy-rated ahead of milestone readouts, trims PT - Investing.com Canada
Piper Sandler cuts Alkermes stock target, keeps Overweight rating By Investing.com - Investing.com Australia
Leerink maintains Alkermes stock rating with $28 target amid financial projections - Investing.com Australia
Leerink maintains Alkermes stock rating with $28 target amid financial projections By Investing.com - Investing.com South Africa
Alkermes (NASDAQ:ALKS) PT Lowered to $30.00 - MarketBeat
Piper Sandler cuts Alkermes stock target, keeps Overweight rating - Investing.com
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down - MSN
Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart
Alkermes' (ALKS) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Alkermes plc (NASDAQ:ALKS) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Alkermes Plc reports solid Q3 growth, eyes future expansion - Investing.com
Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Pro - GuruFocus.com
Substance Abuse Treatment Market to Witness Massive Growth (2024-2031)| Allergan PLC, Alkermes, Noramco. - openPR
Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo Finance
Alkermes: Q3 Earnings Snapshot - mySA
Alkermes' Q3 Proprietary Sales Soar 18% - The Motley Fool
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):